The defendant has already pushed back, denying the claims and signaling a contested fight ahead.

June 23, 2026

Regenerex Pharma has escalated a dispute with a former top executive into open litigation, formalizing a conflict the small Nevada-incorporated drug company first flagged to investors earlier this month.

What the lawsuit alleges

Regenerex Pharma, Inc. disclosed that it has sued Optimize Health Partners, LLC, a Delaware-registered company that operates in Tennessee and is owned by Kenneth W. Perry, the firm’s onetime Chief Financial Officer. The case was filed in Smith County Chancery Court in Tennessee under case number 2026-CV-8819.

The company says its complaint seeks to recover money and other amounts it contends Perry’s entity owes, along with additional relief tied to conduct it attributes to Perry during his time as CFO. Regenerex says it is pursuing the full range of legal and equitable remedies, including:

• monetary damages;
• restitution;
• the return of improper gains, where applicable;
• court orders to halt certain conduct;
• recovery of costs; and
• any further relief the court sees fit to grant.

The company stressed that its accusations have not yet been tested in court and that it cannot predict how the matter will resolve.

Perry is fighting back

The former executive is not contesting the suit quietly. Regenerex said Perry has responded to the complaint, rejecting its central allegations and making clear he intends to mount a defense. The company, for its part, said it plans to press its claims aggressively even though the proceedings remain at an early stage.

Not the first disclosure

The dispute is familiar to followers of the company. Regenerex had already disclosed the litigation in a separate report this month, and the latest update adds two key details: the court venue and Perry’s initial response.

A litigation update dated June 15, 2026 was attached as a supporting exhibit. Greg Pilant, Regenerex’s Chief Executive Officer, signed the report, which carried a report date of June 19, 2026.

Regenerex identifies itself as an emerging growth company, a status that affords smaller, newer public reporters certain accommodations under federal securities rules.